A Phase 3 interventional study of Placebo and Ruxolitinib in COVID-19, sponsored by Incyte Corporation. Terminated at 36 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-01-19.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing ruxolitinib in COVID-19 — none open to participants now, none under way, none of them phase 3. ruxolitinib · COVID-19.
Among the 13 studies testing ruxolitinib in COVID-19, this one is the 3rd largest by enrollment, is one of 12 that started in 2020, is one of 3 in phase 3, and was the 9th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →None of the 13 studies testing ruxolitinib in COVID-19 is open now. The open studies under COVID-19, anywhere →
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 4
First in 2020; this study’s year is marked. 12 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 211 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 94 across the 13 interventional studies. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 13 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
Incyte Corporation has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing ruxolitinib in COVID-19, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with lung imaging showing bilateral or diffuse pulmonary infiltrates on chest x-ray or CT scan.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matching Placebo will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
Drug: Placebo
Ruxolitinib 5mg will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
Drug: Ruxolitinib
Ruxolitinib 15mg will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
Drug: Ruxolitinib
Placebo administered BID approximately 12 hours apart
Ruxolitinb administered BID approximately 12 hours apart
Also known as: INCB018424, Oral Jak Inhibitor
Percentage of Participants Who Have Died Due to Any Cause
To evaluate the 28-day mortality rate of ruxolitinib 5 mg BID + SoC therapy and ruxolitinib 15 mg BID + SoC compared with placebo + SoC therapy, in participants with COVID-19-associated ARDS who require mechanical ventilation.
Time frame: Study start to Day 29
Number of Ventilator Free Days
Number of days participant did not require mechanical ventilation
Time frame: Study start to Day 29
Number of ICU Free Days
Number of days participant is out of the ICU
Time frame: Study start to Day 29
Oxygen Free Days
Number of days participant did not receive supplemental oxygen
Time frame: Study start to Day 29
Vasopressor Free Days
Number of days without use of vasopressor therapy
Time frame: Study start to Day 29
Hospital Free Days
Number of days Partcipant is out of the hospital
Time frame: Study start to Day 29
Percentage of Participants With at Least 2-point Improvement in the COVID-19 Ordinal Scale
Participants with at least 2-point improvement at Day 15 and 29 based on participant state. The scale ranges from 0-8 with 0 being no clinical or virological evidence of infection and 8 being dead
Time frame: Study start to Days 15 and 29
Percentage of Participants With at Least 1-point Improvement in the COVID-19 Ordinal Scale
Participants with at lest 1-point improvement in clinical status at Days 15 and 29 based on participant state. The scale ranges from 0-8 with 0 being no clinical or virological evidence of infection and 8 being dead
Time frame: Study start to Days 15 and 29
Time to Improvement From Baseline Category to Earliest 1-point Improvement in the COVID-19 Ordinal Scale
TIme to improvement compared to baseline. The scale ranges from 0-8 with 0 being no clinical or virological evidence of infection and 8 being dead
Time frame: Study Start to Day 29
Percentage of Participants With the COVID-19 Ordinal Scale Reported
Clinical status of participant at Day 29 based on participant state. The scale ranges from 0-8 with 0 being no clinical or virological evidence of infection and 8 being dead
Time frame: Study start to Day 29
Change in the COVID-19 9-point Ordinal Scale
Change in the Clinical status of participant at Days 15 and 29 based on participant state. The scale ranges from 0-8 with 0 being no clinical or virological evidence of infection and 8 being dead
Time frame: Study start to Days 15 and 29
Change in SOFA Score
Sequential Organ Failure Assessment (SOFA) score is a scoring system to determine the extent of a person's organ function or rate of failure. The score is based on 6 different scores, 1 each for the respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems. Each system gets a score from 0 (normal) to 4 (abnormal) and the sum of each score defines the final SOFA score, which 24 is the maximum score (high risk of morality) and 0 is the minimum score (low risk of mortality).
Time frame: from baseline to Days 3, 5, 8, 11, 15, and 29
Number and Percentage of Participants With Treatment-related Side Effects and Serious Adverse Events
Treatment-emergent AEs are judged as related by the investigator or have a missing causality.
Time frame: Study start to Day 29
This study was conducted at 33 study centers in the United States (29) and Russia (4), and 211 participants were enrolled and analyzed for efficacy.; 209 participants were analyzed for safety. Enrollment in this study was stopped early and was not due to safety reasons.
| Milestone | Ruxolitininb 15mg + Standard of Care | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) |
|---|---|---|---|
| Started | 77 | 87 | 47 |
| Completed | 35 | 37 | 11 |
| Not completed | 42 | 50 | 36 |
| Withdrew: Death | 42 | 48 | 36 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 |
To evaluate the 28-day mortality rate of ruxolitinib 5 mg BID + SoC therapy and ruxolitinib 15 mg BID + SoC compared with placebo + SoC therapy, in participants with COVID-19-associated ARDS who require mechanical ventilation.
| Percentage | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) |
|---|---|---|---|
| Percentage of Participants Who Have Died Due to Any Cause | 50.6 | 52.9 | 70.2 |
Number of days participant did not require mechanical ventilation
| Days | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) |
|---|---|---|---|
| Number of Ventilator Free Days | 6.31 ± 9.047 | 4.92 ± 8.398 | 2.98 ± 7.228 |
Number of days participant is out of the ICU
| Days | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) |
|---|---|---|---|
| Number of ICU Free Days | 4.75 ± 7.716 | 4.00 ± 7.517 | 2.45 ± 6.362 |
Number of days participant did not receive supplemental oxygen
| Days | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) |
|---|---|---|---|
| Oxygen Free Days | 2.66 ± 6.073 | 2.98 ± 6.745 | 1.53 ± 4.690 |
Number of days without use of vasopressor therapy
| Days | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) |
|---|---|---|---|
| Vasopressor Free Days | 8.95 ± 11.738 | 7.53 ± 10.861 | 4.47 ± 9.322 |
Number of days Partcipant is out of the hospital
| Days | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) |
|---|---|---|---|
| Hospital Free Days | 2.09 ± 4.889 | 2.35 ± 5.259 | 1.38 ± 3.976 |
Participants with at least 2-point improvement at Day 15 and 29 based on participant state. The scale ranges from 0-8 with 0 being no clinical or virological evidence of infection and 8 being dead
| Percentage of Participants | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) |
|---|---|---|---|
| Day 15 | 22.1 (13.4 to 33.) | 15.3 (8.4 to 24.7) | 10.6 (3.5 to 23.1) |
| Day 29 | 29.7 (19.7 to 41.5) | 25.3 (16.4 to 36.0) | 17.0 (7.6 to 30.8) |
Participants with at lest 1-point improvement in clinical status at Days 15 and 29 based on participant state. The scale ranges from 0-8 with 0 being no clinical or virological evidence of infection and 8 being dead
| Percentage of Participants | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) |
|---|---|---|---|
| Day 15 | 41.6 (30.4 to 53.4) | 32.9 (23.1 to 44.0) | 21.3 (10.7 to 35.7) |
| Day 29 | 43.2 (31.8 to 55.3) | 32.5 (22.6 to 43.7) | 17.0 (7.6 to 30.8) |
TIme to improvement compared to baseline. The scale ranges from 0-8 with 0 being no clinical or virological evidence of infection and 8 being dead
| Days | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) |
|---|---|---|---|
| Time to Improvement From Baseline Category to Earliest 1-point Improvement in the COVID-19 Ordinal Scale | 0.91 (0.711 to 0.992) | 0.75 (0.614 to 0.867) | 0.61 (0.408 to 0.818) |
Clinical status of participant at Day 29 based on participant state. The scale ranges from 0-8 with 0 being no clinical or virological evidence of infection and 8 being dead
| Percentage | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) |
|---|---|---|---|
| Score 0 = Uninfected | 0 | 4.6 | 0 |
| Score 1 = Ambulatory (no limitation of activities) | 2.6 | 0 | 2.1 |
| Score 2 = Ambulatory (limitation of activities) | 16.9 | 16.1 | 10.6 |
| Score 3 = Hospitalized/Mild Disease (no oxygen therapy) | 0 | 1.1 | 0 |
| Score 4 = Hospitalized/Mild Disease (oxygen therapy via mask or nasal prongs) | 9.1 | 1.1 | 4.3 |
| Score 5 = Hospitalized/Severe Disease (non-invasive ventilation or high-flow oxygen) | 3.9 | 4.6 | 0.0 |
| Score 6 = Hospitalized/Severe Disease (intubationand mechanical ventilization) | 10.4 | 8.0 | 2.1 |
| Score 7 = Hospitalized/Severe Disease (ventilation + additional organ support) | 2.6 | 8.0 | 10.6 |
| Score 8 - Death | 50.6 | 51.7 | 70.2 |
Change in the Clinical status of participant at Days 15 and 29 based on participant state. The scale ranges from 0-8 with 0 being no clinical or virological evidence of infection and 8 being dead
| Score on a Scale | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) |
|---|---|---|---|
| Change from Day 1 to Day 15 | -0.4 ± 1.80 | -0.2 ± 1.73 | 0.6 ± 1.69 |
| Change from Day 1 to Day 29 | -0.5 ± 2.53 | -0.4 ± 2.57 | 0.4 ± 2.23 |
Sequential Organ Failure Assessment (SOFA) score is a scoring system to determine the extent of a person's organ function or rate of failure. The score is based on 6 different scores, 1 each for the respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems. Each system gets a score from 0 (normal) to 4 (abnormal) and the sum of each score defines the final SOFA score, which 24 is the maximum score (high risk of morality) and 0 is the minimum score (low risk of mortality).
| Scores on a Scale | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) |
|---|---|---|---|
| Baseline - Day 1 | 9.2 ± 2.35 | 9.6 ± 2.53 | 9.4 ± 2.69 |
| Day 3 | -0.1 ± 2.77 | 0.4 ± 3.14 | 2.6 ± 5.89 |
| Day 5 | 0.2 ± 4.27 | 0.7 ± 4.58 | 3.3 ± 6.60 |
| Day 8 | 1.9 ± 6.77 | 2.0 ± 6.30 | 4.5 ± 7.87 |
| Day 11 | 2.5 ± 7.64 | 2.0 ± 7.02 | 6.5 ± 8.26 |
| Day 15 | 4.2 ± 9.24 | 4.1 ± 7.72 | 10.3 ± 7.89 |
| Day 29 | 10.3 ± 8.54 | 10.4 ± 7.04 | 12.8 ± 5.41 |
Treatment-emergent AEs are judged as related by the investigator or have a missing causality.
| Participants | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) |
|---|---|---|---|
| Treatment-Emergent Adverse Events (TEAEs) | 22 | 23 | 11 |
| Serious TEAEs | 23 | 21 | 11 |
Collected over Up to approximately 2 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib 15 mg BID | 42/77 (54.5%) | 23/77 (29.9%) | 35/77 (45.5%) |
| Ruxolitinib 5 mg BID | 48/87 (55.2%) | 21/87 (24.1%) | 46/87 (52.9%) |
| Placebo | 36/47 (76.6%) | 11/45 (24.4%) | 21/45 (46.7%) |
| Total | 124/209 (59.3%) | 55/209 (26.3%) | 102/209 (48.8%) |
| Event | Ruxolitinib 15 mg BID | Ruxolitinib 5 mg BID | Placebo | Total |
|---|---|---|---|---|
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/77 | 1/87 | 3/45 | 5/209 |
| PneumoniaInfections and infestations | 2/77 | 4/87 | 2/45 | 8/209 |
| Alanine aminotransferase increasedInvestigations | 3/77 | 1/87 | 1/45 | 5/209 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 3/77 | 0/87 | 1/45 | 4/209 |
| SepsisInfections and infestations | 3/77 | 1/87 | 0/45 | 4/209 |
| HypotensionVascular disorders | 1/77 | 3/87 | 1/45 | 5/209 |
| Aspartate aminotransferase increasedInvestigations | 2/77 | 1/87 | 1/45 | 4/209 |
| HypertensionVascular disorders | 2/77 | 1/87 | 0/45 | 3/209 |
| Acute kidney injuryRenal and urinary disorders | 1/77 | 2/87 | 0/45 | 3/209 |
| Blood alkaline phosphatase increasedInvestigations | 0/77 | 2/87 | 0/45 | 2/209 |
| Event | Ruxolitinib 15 mg BID | Ruxolitinib 5 mg BID | Placebo | Total |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 12/77 | 21/87 | 9/45 | 42/209 |
| HypernatraemiaMetabolism and nutrition disorders | 8/77 | 7/87 | 7/45 | 22/209 |
| Alanine aminotransferase increasedInvestigations | 9/77 | 12/87 | 5/45 | 26/209 |
| Aspartate aminotransferase increasedInvestigations | 10/77 | 11/87 | 3/45 | 24/209 |
| HypertensionVascular disorders | 5/77 | 11/87 | 5/45 | 21/209 |
| HypokalaemiaMetabolism and nutrition disorders | 9/77 | 9/87 | 4/45 | 22/209 |
| HyperglycaemiaMetabolism and nutrition disorders | 3/77 | 8/87 | 1/45 | 12/209 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 1/77 | 7/87 | 4/45 | 12/209 |
| PyrexiaGeneral disorders | 2/77 | 5/87 | 4/45 | 11/209 |
| AnxietyPsychiatric disorders | 6/77 | 4/87 | 1/45 | 11/209 |
Intent-to-treat (ITT) population included all participants who were randomized to the study.
| Age, Continuous(Years) | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) | Total |
|---|---|---|---|---|
| Mean | 63.6 ± 12.92 | 63.6 ± 12.25 | 62.5 ± 13.34 | 63.4 ± 12.69 |
| Sex: Female, Male(Participants) | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) | Total |
|---|---|---|---|---|
| Female | 29 | 32 | 13 | 74 |
| Male | 48 | 55 | 34 | 137 |
| Ethnicity (NIH/OMB)(Participants) | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 21 | 21 | 12 | 54 |
| Not Hispanic or Latino | 53 | 64 | 34 | 151 |
| Unknown or Not Reported | 3 | 2 | 1 | 6 |
| Race (NIH/OMB)(Participants) | Ruxolitininb 15mg + Standard of Care (SoC) | Ruxolitinib 5mg + Standard of Care (SoC) | Placebo + Standard of Care (SoC) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 2 | 2 |
| Asian | 3 | 3 | 1 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 9 | 12 | 5 | 26 |
| White | 57 | 61 | 31 | 149 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 8 | 11 | 8 | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from May 2020 to primary completion in Feb 2021, 9 months.
Results were first posted in Jan 2022, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib